Muhammad Umair Mushtaq

2 months ago | cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari

January 31, 2025By Panelists discuss how expanding CAR T therapy into earlier lines of multiple myeloma treatment requires careful evaluation of clinical trial data, infrastructure readiness, patient selection criteria, and manufacturing capacity while balancing the therapy’s potential benefits against established treatment approaches.

2 months ago | cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari

January 31, 2025By Panelists discuss how successful comanagement of CAR T-cell therapy cases requires close coordination between academic centers and community practices, with structured protocols for monitoring, communication, and patient handoffs, while addressing challenges in referral timing, resource allocation, and long-term follow-up care.

Jan 24, 2025 | cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari

January 24, 2025By Panelists discuss how CAR T-cell therapy, a groundbreaking immunotherapy treatment, works by extracting a patient’s T cells, genetically modifying them to target cancer cells, and reinfusing them back into the patient’s body through a process that involves close monitoring and specialized careVideo content above is prompted by the following:Could you explain how CAR T-cell therapy works and describe the treatment process at University of Kansas Medical Center?

Jan 24, 2025 | cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari

January 24, 2025By Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes. Video content above is prompted by the following:Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?

Jan 20, 2025 | cancernetwork.com | Al-Ola Abdallah |Muhammad Umair Mushtaq |Jeries Kort |Zahra Mahmoudjafari

January 20, 2025By Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.